TargetMol

Xanthine

Product Code:
 
TAR-T0665
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0665-500mg500mg£104.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0665-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0665-1g1g£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Xanthine is a product on the pathway of purine degradation. Xanthine is subsequently converted to uric acid by the action of the Xanthine oxidase enzyme. Xanthine is found in most body tissues and fluids in various organisms. Biologically Xanthine is produced from guanine by cypin (guanine deaminase). Furthermore, Xanthines act as antagonists for adenosine receptors, with selectivity depending on whether there are substitution of alkyl groups.
CAS:
69-89-6
Formula:
C5H4N4O2
Molecular Weight:
152.113
Pathway:
Metabolism; GPCR/G Protein; Neuroscience
Purity:
0.8906
SMILES:
O=c1[nH]c2nc[nH]c2c(=O)[nH]1
Target:
Endogenous Metabolite; Adenosine Receptor

References

1. SMITH SC, et al. The use of amberlite resin in a separation of xanthine and guanine. J Am Chem Soc. 1948 Nov;70(11):3719. 2. Daly JW, Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. 3. Overington JP, et al. Nat Rev Drug Discov. 2006 Dec;5(12):1993-6.